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ABSTRACT
Next-generation sequencing has proven an ex-
tremely effective technology for molecular
counting applications where the number of
sequence reads provides a digital readout for
RNA-seq, ChIP-seq, Tn-seq and other applications.
The extremely large number of sequence reads that
can be obtained per run permits the analysis of
increasingly complex samples. For lower complexity
samples, however, a point of diminishing returns is
reached when the number of counts per sequence
results in oversampling with no increase in data
quality. A solution to making next-generation
sequencing as efficient and affordable as possible
involves assaying multiple samples in a single run.
Here, we report the successful 96-plexing of
complex pools of DNA barcoded yeast mutants
and show that such ‘Bar-seq’ assessment of these
samples is comparable with data provided by
barcode microarrays, the current benchmark for
this application. The cost reduction and increased
throughput permitted by highly multiplexed
sequencing will greatly expand the scope of
chemogenomics assays and, equally importantly,
the approach is suitable for other sequence
counting applications that could benefit from
massive parallelization.
INTRODUCTION
Next-generation sequencing (NGS) technologies can
generate up to several hundred million reads of DNA
sequence per lane or slide, and this capacity continues to
increase at a rapid pace. This massive capacity has allowed
exploration of diverse biological questions (1–4).
Although pooled chemogenomic screens of compound–
gene interactions in yeast (5–16) and mammalian cells
(17,18) are typically assessed using barcode microarrays,
counting of individual strains could also be assessed by
barcode sequencing. We recently developed such an
assay (Bar-seq) to monitor thousands of gene–chemical
interactions (19). We now expand upon this proof-
of-principle to interrogate 96 samples in parallel, develop-
ing the methodology and analytical tools to use NGS
to simultaneously monitor several hundred thousand
gene–environment interactions using a method
that should be readily adaptable to an automated
workﬂow.
Here, we demonstrate successful multiplexing of
samples obtained from 96 distinct pooled yeast growth
assays, with each sample comprising 6200 uniquely
barcoded yeast mutants. This 96-plex experiment repre-
sents a 150-fold increase in unique observations over our
proof-of-principle assessment, and provides substantial
cost reduction/experiment over microarrays.
Furthermore, while many aspects of microarray assay
costs are ﬁxed, the cost of multiplex barcode sequencing
continues to decline as the number of reads per experiment
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recently been shown to outpace the rate of Moore’s law
(20). To assess the data quality at this level of multiplex-
ing, all 96 samples were also assessed by microarray and
we then compared the ability of both platforms to detect
speciﬁc compound–gene interactions. It is expected that
the principle of this 96-fold multiplexing application,
with its ability to discriminate many sample types/slide
or ﬂow cell can be applied, with modiﬁcation, to other
molecular counting methods such as RNA-seq (21),
ChIP-seq (22), promoter assays (23), histone occupancy
(24) and Tn-seq (25). To systematically test highly multi-
plexed Bar-seq, we required a large pool of distinct
sequences whose relative abundances could be varied
and whose quantities could also be assessed by an orthog-
onal method. The Yeast Knock Out collection of
6200 Saccharomyces cerevisiae mutants, although
designed for testing gene function, provides a suitable
test bed for new sequencing methods (19). Each yeast
deletion mutant contains three salient features: a
dominant drug resistance marker replacing the deleted
gene; two unique 20 base molecular barcodes; and univer-
sal primers that ﬂank each barcode to allow ampliﬁcation
of all barcodes in a pooled manner using a single set
of primers. Pooled competitive growth assays are typically
carried out on 6200 mutants, and their relative
abundances inferred from the signal from a barcode
microarray (5–16). The rapid pace of advance in
sequencing depth have led us and others to exploring
diverse strategies for multiplexing of samples for NGS
samples (19,25–34).
One essential element for multiplexing prior to
sequencing is the incorporation (in this instance using
modiﬁed primers during PCR) of a unique experimental
indexing tag (See Supplementary Figure S1 for structure
of PCR amplicon). Following PCR, the ampliﬁed DNA is
puriﬁed and quantiﬁed, then pooled with amplicons
derived from other samples with diﬀerent indexing tags.
The pooled PCR products are then puriﬁed from a single
lane of a polyacrylamide gel, reducing costs and sample
preparation time. Further, combining samples prior to
puriﬁcation reduces potential liquid transfer errors,
providing for greater uniformity, and also reducing the
number of emulsion PCRs reactions required prior to
di-nucleotide sequencing on the SOLiD V3 instrument.
In our 20- and 96-plex sequencing runs, two independent
reads were obtained for each feature (Supplementary
Figure S1): the ﬁrst sequence read was primed from the
P1 adapter sequence, capturing the sequence of the ﬁrst
common primer (U1) and the yeast barcode. The second
sequencing read, primed from the IA internal adaptor
captures the SOLiD indexing tag used to assign barcode
reads to 96 individual sample bins. Data from a real-world
96-plex assay show performance equal to or exceeding
both microarray data and published lower complexity
multiplexing Bar-seq data. The potential for higher
order multiplexing of thousands of samples oﬀers the
prospect of greatly reduced cost and such ‘extreme-
multiplexing’ will beneﬁt from robust automation to
ensure sample uniformity.
METHODS AND MATERIALS
Yeast deletion collection
The yeast deletion collection was obtained from Angela
Chu at the Stanford Genome Technology Centre, and
stored in YPD-7% dimethyl sulfoxide (DMSO) in  80 C
as individual strains in 96-well plates. The plates were
thawed and robotically pinned onto YPD agar plates.
Cells are grown in 30 C for 2–3 days until colonies form.
Slow growing strains were grown separately for 2–3 add-
itional days. All plates were then ﬂooded with 5–7ml of
media, scraped and pooled in YPD-7% DMSO to a ﬁnal
concentration of OD600=50, and frozen at  80 C until
use, as described by Pierce et al. (11).
Construction of pools with ﬁxed numbers of barcoded
strains
A pool of 953 diﬀerent heterozygous mutants was selected
to contain two well-known drug targets as heterozygous
deletions. ‘Pool-constant’ was constructed by growing
each strain in 100ml of YPD to saturation in 96-well
plates then pooling 20ml from each well, so that all 953
strains in this pool are at approximately the same abun-
dance. ‘Pool-variable’ consisted of the same 953 strains
but in this pool, the number of cells of each strain was
varied systematically with one-quarter of the 953 strains
added at one of the following ratios (2:1:0.5:0.25) with
respect to Pool-constant.
Pooled growth assays
Two deletion pools, a homozygous deletion pool of 5054
strains representing non-essential genes and a heterozy-
gous pool of 1194 strains representing genes essential for
viability, were thawed and diluted in YPD to an OD600 of
0.0625. Seven hundred microliters of cultures were grown
at 30 C with a chemical inhibitor applied at a dose that
produced 10–20% growth inhibition of wild-type. An
automated liquid handler was used to maintain logarith-
mic growth of pools (by dilution), and to collect 0.7
OD600s of heterozygous pool following 20 generations of
growth, and 1.4 OD600s of homozygous pool following
ﬁve generations of growth.
Assessing ﬁtness of barcoded yeast strains by barcode
microarray
Except where indicated, pooled assays were performed as
described by Pierce et al. (11). Genomic DNA was isolated
from cells and barcodes ampliﬁed and hybridized to
barcode microarrays, where each barcode deletion
mutant is represented by 10 hybridization signals (an
uptag and downtag for each strain, each present on the
array ﬁve times). Array signals were quantile normalized
such that all tags hybridized with the sample pool had
similar distributions. Following normalization, a correc-
tion factor was applied to the array data to correct for
feature saturation (11) and the ﬁtness of each barcoded
deletion strain determined using the uptag barcodes only
(to compare to the sequencing samples which contained
only uptags as well). Positive ﬁtness defect scores signify a
decrease in strain abundance during drug treatment and
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that strain is required for resistance to that drug or
inhibitor.
Assessing ﬁtness of barcoded yeast strains by SOLiD
sequencing
DNA was isolated from the deletion pools as described
(11). Each 20-mer uptag barcode was ampliﬁed with com-
posite primers comprised of the sequences of the common
barcode primers and the sequences required for attach-
ment to the SOLiD slide. For the Uptags the following
primers were used:
50-CTGCCCCGGGTTCCTCATTCTCTNNNNNNNN
NNCTGCTGTACGGCCAAGGCGGTCGACCTGCAG
CGTACG-30 (Forward) and
50-CCTCTCTATGGGCAGTCGGTGATGATGTCCA
CGAGGTCTCT-30 (Reverse). The 50 portion (in bold) are
the P2 and P1 sequences incorporated into the F and R
primer, respectively. The variable sequence (italics) repre-
sents the 10-mer indexing tag used for multiplexing. The
internal adaptor (IA) sequence (bold italics) is required to
sequence the SOLiD multiplexing tags. The 30 portion
(underlined) represents the common primer ﬂanking the
uptag barcode and is required to amplify the yeast
barcodes. PCR ampliﬁcation was conducted in 100ml
volumes, using Invitrogen Platinum PCR Supermix (Cat.
No. 11306-016) with the following conditions: 95 C/3min;
25 cycles of 94 C/30s, 55 C/30s, 68 C/30s; followed by
68 C/10min. PCR product was then puriﬁed with Qiagen
MinElute
TM 96 UF PCR Puriﬁcation Kit (Cat. No.
28051). Following PCR puriﬁcation, DNA was quantiﬁed
with the Invitrogen Quant-iT
TM dsDNA BR Assay Kit
(Cat No. Q32853) and then adjusted to a concentration
of 10mg/ml. Equal volumes of normalized DNAs were
then pooled. This pooled DNA (20- and 96-plex) consist-
ing of 130-bp PCR products was gel puriﬁed from 12%
polyacrylamide TBE gels using the crush and soak method
(35) followed by ethanol precipitation. Samples were used
directly for emulsion PCR and bead enrichment. Each
bead on the slide was hybridized twice, ﬁrst to the P1
primer to sequence the yeast barcode (SOLiD Fragment
Library Sequencing kit—Master Mix 50 Cat No. 4406370;
SOLiD 3 Instrument Buﬀer kit Cat No. 4406479) and then
to the internal adaptor (IA) to sequence the SOLiD multi-
plexing tag (SOLiD Fragment Library Sequencing kit
Barcode set Cat No. 4406447). The 10-base multiplexing
tag allowed postsequencing assignment of each amplicon
to a particular experiment. The identity of each bead’s
multiplexing tag was determined allowing 0 mismatches.
To analyze the Bar-seq data, all counts were quantile
normalized such that each experiment had the same
count distribution. By analogy with barcode microarray
ﬁtness experiments, ﬁtness defect ratios for each strain
were calculated and expressed as the log2 ratio (control/
treatment).
RESULTS
As a proof of principle, we performed a 20-plex analysis of
ﬁve samples; two untreated controls and three chemically
treated samples (four replicates each plus a spike-in
control consisting of ﬁve unique samples). We found an
average correlation of r=0.989 between raw, unﬁltered
counts in replicate experiments, indicating the sequencing
assay is highly reproducible. The same ﬁve samples were
hybridized to barcode microarrays. Treatment of the yeast
deletion pool with the DNA damaging agent cisplatin
resulted in ﬁtness defects in strains deleted for a variety
of DNA repair genes, when either sequencing or array
were used as the readout [Figure 1a and Supplementary
Table S1 (10)]. Treatment of the yeast deletion pool with
the drug cervistatin showed a similar concordance
between Bar-seq and array readouts. For example, in
cervistatin treatment the strain deleted for Hmg1 [the
known drug target (19)] scored as one of the top hits in
both the microarray and Bar-seq assays (Supplementary
Figure S2). The ﬁtness defect ratios across all strains were
well correlated (r=0.739).
We next expanded the degree of multiplexing from 20 to
96 individual experiments. The 96-plex experiment
includes 12 DMSO-treated vehicle controls, 84 drug-
treated samples and 5 spike-in controls. The experimental
samples were selected based on the availability of existing
hybridization data from our laboratory.
To assess our ability to resolve data from a 96-plex ex-
periment, we ﬁrst examined the spike-in controls that con-
sisted of a pool of 953 yeast deletion mutants combined at
the same relative abundance (Pool-constant). This pool
was ampliﬁed in four separate PCR reactions, each
reaction having a diﬀerent multiplexing primer with a
unique SOLiD indexing tag. Each sample was added to
the sequencing reaction at 1 of 4 relative quantities (1 ,
2 ,4   or 8 ). Comparison between these samples using
count ratios (Supplementary Figure S3) indicated that
there were suﬃcient sequencing counts in the 96-plex ex-
periment to identify a 4-fold diﬀerence in barcode abun-
dance between two samples. While the counts do not
scatter symmetrically around the expected ratio line
(likely reﬂecting slight imprecision at the pooling step)
the populations are distinct. Figure 1b shows two samples
from the 96-plex that clearly reveal distinct drug targets.
Methyl methanesulfonate (MMS), a DNA damaging
agent, shows that the Rad5 deletion strain exhibits a prom-
inent ﬁtness defect after analysis by both multiplexed NGS
and microarray [Supplementary Table 2 (10)]. Results
obtained with a second, previously uncharacterized
compound 1561-0023 (from ChemDiv, Inc.) suggest that
it may be an inhibitor of Pkc1, a serine/threonine kinase
involved in cell wall remodeling during growth (36). We
compared the structure of this inhibitor to 150 known
Pkc1 inhibitors present in the ‘Chembl’ database
(http://www.ebi.ac.uk/chembldb/index.php using
ECFP_4 ﬁngerprints to represent the structures and a
Tanimoto score cutoﬀ of >0.3). This analysis found no
similar structures, suggesting this compound is a potential-
ly novel chemical probe for inhibiting Pkc1.
To assess if increasing the degree of multiplexing from
20 to 96 aﬀected either data quality or data reproducibil-
ity, we examined the correlation of signal ratios in the
spike-in samples that were present in both sequencing
runs, using Pool-constant (at 8  abundance) and a
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levels of abundance relative to Pool-constant (i.e. 2 ,
1 , 0.5  and 0.25  of Pool-constant). Ratios were
highly correlated between 20- and 96-plex runs
(r=0.943; Figure 2). Since the same pool of 953 strains
had previously been assessed with an Illumina Genome
Analyzer IIx, we performed a cross-platform comparison.
The ratios showed a strong agreement between both
methods with correlations of, r=0.866, 0.896 for the
SOLiD 20- and 96-plex, respectively (Figure 2). The
ratios calculated by microarray analysis were similar to
ratios calculated on either platform at each level of multi-
plexing (r ranging from 0.695–0.746; Figure 2).
We also assessed the performance of the SOLiD multi-
plexing tags used in the 96-plex experiment. Speciﬁcally,
index tags were ﬁrst assigned to samples only when there
was a perfect match to the expected sequence. We then
reanalyzed this data to allow up to two mismatches to the
index sequence to ask if additional reads could be mapped,
without degrading performance due to misaligned reads.
In total,  320 million reads were collected in the 96-plex
experiment (including spike-in controls, this sample com-
prises 104 diﬀerent index sequences). Of these sequences,
64.5% were separated into bins based on a perfect match
to the 10-bp index sequence. Of the 96 samples generated
from the complete pool, the average bin size was 2.1
million reads. The coeﬃcient of variation across these 96
samples was 19%.
By allowing either one or two mismatches in the index
sequence, the total percentage of reads binned increased
from 64.5% to 80%. With one mismatch, the percentage
increase across the 96 bins ranges between 5.5% and
14.8%, with a further increase of 6.0–17% observed
with two mismatches (Supplementary Table S3 and
Figure S4).
We examined a number of sequence characteristics in
the index sequence to identify any factors that might con-
tribute to the variation in the increased bin sizes after
allowing mismatches. The GC content of the 10-base
index ranged between 20% and 80% with a median GC
content of 50%. No correlation was observed between the
GC content and the increased bin sizes after either one or
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Figure 1. (a) The log2 ratio of control versus treatment for one example from the 20-plex Bar-seq data. The x-axis is the log2 ratio derived from the
Bar-seq data, while the y-axis is the log2 ratio derived from barcode microarray data. The proﬁles are from a 100mM cisplatin treatment. The black
dots represent genes above our threshold; greater than 200 signal intensity in the barcode microarray and greater than 40 barcode sequence counts in
the Bar-seq. (b) The log2 ratio of control over treatment for two examples from the 96-plex Bar-seq data. The x-axis is the log2 ratio derived from
the Bar-seq data, the y-axis is the log2 ratio derived from barcode microarray data. The left panel shows the result from 91-mM MMS treatment, the
right panel shows the proﬁle obtained with an uncharacterized compound 1561-0023 screened at 0.372mM. The black dots represent genes which
were above our threshold; greater than 200 signal intensity in the barcode microarray and greater than 40 barcode sequence counts in Bar-seq.
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GC content at the extremes (20%, 80%) did not show
signiﬁcant diﬀerences in bin increases versus index se-
quences with balanced GC. Mononucleotide runs of 3 or
4 bases were observed in 31 and 4% of the index se-
quences, respectively. Index sequences containing these
runs did not diﬀer signiﬁcantly from those that did not
have these runs with respect to the increases in bin size
after allowance of mismatches. We next examined vari-
ation in the dinucleotide pair at the end of the index
barcode immediately 30 to the sequencing primer. Of the
16 possible dinucleotides, 13 were present. No signiﬁcant
diﬀerences were seen across these classes. Finally, to de-
termine if any of the index sequences introduced a second-
ary structure that might aﬀect sequencing accuracy. We
determined the free energy (37) of the 70-base sequence
common to all reactions, which diﬀered only by the index
sequence (sequencing primer/adapter+index+spacer+
upstream barcode). Maximal free energies ranged
between  11.69 and  5.04kcal/mol. No correlation was
seen between free energy and increases in bin sizes after
allowance of mismatches.
A few index barcodes in the 96-plex experiment dis-
played relatively large increases in bin size after allowance
of mismatches compared with most of the sequences.
These all appeared in the ﬁve samples generated from
contrived pools (bins 100–104). After allowance of a
single mismatch in the index barcode, bin 100 increased
by 53%, followed by a further 24% increase after allow-
ance of two mismatches. After two mismatches, bins 102
and 103 also increased by 32 and 45%, respectively
(Supplementary Table S3 and Figure S4). No primary
sequence characteristic was observed in these index se-
quences, which was also not observed in the other index
sequences. For these three indexes, the GC content was
either 40 or 50%, only a single mononucleotide run of 3
bases was observed, the dinucleotide end sequences were
not unique and the free energy was at the less negative end
of the range, suggesting less secondary structure interfer-
ence. Based on this initial analysis of the index sequences,
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Figure 2. Scatter plots of the Log2 ratio of the Pool-constant versus the Pool-variable. The data were generated on three diﬀerent platforms, barcode
microarray, Illumina/Solexa, and SOLiD. The SOLiD data is derived from 20- and 96-plex samples. The r-value is indicated for each comparison and
the line of best ﬁt is plotted. Data presented were ﬁltered for barcodes that were present in both Illumina/Solexa and SOLiD sequencing counts with
counts greater than zero in both platforms.
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performance for this application is robust.
DISCUSSION
We previously determined, by simulation, that a minimum
of 50 counts per barcode was suﬃcient for accurate assess-
ment of strain abundance in Bar-seq analysis (19). In the
96-plex experiment each barcode was counted, on average,
262 times (ranging from 111 counts to 383 counts/
barcode). In contrast, the 20-plex experiment counted
each barcode an average of 1224 times. Both the counts
between replicates and the relative strain abundance in our
spike-in pools are highly correlated between the 20- and
96-plex runs, suggesting that empirically 100–300 counts/
barcode is suﬃcient. Additional studies will be required to
determine the actual lower limit of counts at diﬀerent false
discovery thresholds. From a practical perspective, we
were able to clearly identify drug targets in many of the
experiments in the 96-plex run (Figure 1b), suggesting
higher order (>96) multiplexing can be achieved. Fitness
defect ratios for all strains/pool were highly correlated
across diﬀerent platforms (SOLiD, Illumina/Solexa and
microarray; Figure 2). This matched sequencing array
data set of a 20- and 96-plex samples should be useful
for assessment of platform-speciﬁc performance.
Furthermore, given the similarity in experimental design
of yeast deletion pool experiments and highly multiplexed
shRNA assays in mammalian cells (38), the methods
described here should translate well to these more
complex pooled assays.
Finally, the data presented in this study may prove
useful by providing a large data set to augment
computer-aided barcode design eﬀorts (33,39,40), which
will become increasingly important as the levels of multi-
plexing increase further. In summary, we present a robust
96-plex method for sequencing pools of medium complex-
ity (1000–50000 members/pool) that should be applicable
to other sequencing applications.
SUPPLEMENTARY DATA
Supplemental ﬁgures are available at NAR Online. Raw
data available at: http://chemogenomics.med.utoronto.ca/
supplemental/multiplex/.
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